Advances in viral vector-based TRAIL gene therapy for cancer

Cancers

Volumn 3, Issue 1, 2011, Pages 603-620

  Norian, Lyse A ^a   James, Britnie R ^a   Griffith, Thomas S ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Apoptosis; Cancer; Gene therapy; TRAIL; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; BORTEZOMIB; DEATH RECEPTOR 4; DEATH RECEPTOR 5; HISTONE DEACETYLASE INHIBITOR; PARVOVIRUS VECTOR; SORAFENIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 4; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; COLORECTAL CANCER; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION; GLIOMA; HUMAN; IN VITRO STUDY; KIDNEY CARCINOMA; LIVER CANCER; LUNG CANCER; MULTIPLE MYELOMA; NONHUMAN; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TOXICITY TESTING; UPREGULATION; VIRAL GENE THERAPY;

EID: 79953695069     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3010603     Document Type: Review

References (114)

1. Wei, M.C.; Zong, W.X.; Cheng, E.H.; Lindsten, T.; Panoutsakopoulou, V.; Ross, A.J.; Roth, K.A.; MacGregor, G.R.; Thompson, C.B.; Korsmeyer, S.J. Proapoptotic Bax and Bak: A requisite gateway to mitochondrial dysfunction and death. Science 2001, 292, 727-730.
2. Testa, U. Trail/trail-r in hematologic malignancies. J. Cell. Biochem. 2010, 110, 21-34.
3. Zamai, L.; Ahmad, M.; Bennett, I.M.; Azzoni, L.; Alnemri, E.S.; Perussia, B. Natural killer (NK) cell-mediated cytotoxicity: Differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med. 1998, 188, 2375-2380.
4. Mellier, G.; Huang, S.; Shenoy, K.; Pervaiz, S. Trailing death in cancer. Mol. Aspects Med. 2010, 31, 93-112.
5. Holoch, P.A.; Griffith, T.S. TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies. Eur. J. Pharmacol. 2009, 625, 63-72.
6. Rosevear, H.M.; Lightfoot, A.J.; Griffith, T.S. Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer. Curr. Opin. Investig. Drugs 2010, 11, 688-698.
7. Griffith, T.S.; Rauch, C.T.; Smolak, P.J.; Waugh, J.Y.; Boiani, N.; Lynch, D.H.; Smith, C.A.; Goodwin, R.G.; Kubin, M.Z. Functional analysis of TRAIL receptors using monoclonal antibodies. J. Immunol. 1999, 162, 2597-2605.
8. Wiezorek, J.; Holland, P.; Graves, J. Death receptor agonists as a targeted therapy for cancer. Clin. Cancer Res. 2010, 16, 1701-1708.
9. Wiley, S.R.; Schooley, K.; Smolak, P.J.; Din, W.S.; Huang, C.P.; Nicholl, J.K.; Sutherland, G.R.; Smith, T.D.; Rauch, C.; Smith, C.A.; et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3, 673-682.
10. Pitti, R.M.; Marsters, S.A.; Ruppert, S.; Donahue, C.J.; Moore, A.; Ashkenazi, A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 1996, 271, 12687-12690.
11. Cha, S.S.; Kim, M.S.; Choi, Y.H.; Sung, B.J.; Shin, N.K.; Shin, H.C.; Sung, Y.C.; Oh, B.H. 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 1999, 11, 253-261.
12. Griffith, T.S.; Wiley, S.R.; Kubin, M.Z.; Sedger, L.M.; Maliszewski, C.R.; Fanger, N.A. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 1999, 189, 1343-1354.
13. Fanger, N.A.; Maliszewski, C.R.; Schooley, K.; Griffith, T.S. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Exp. Med. 1999, 190, 1155-1164.
14. Kemp, T.J.; Moore, J.M.; Griffith, T.S. Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation. J. Immunol. 2004, 173, 892-899.
15. Kemp, T.J.; Ludwig, A.T.; Earel, J.K.; Moore, J.M.; Vanoosten, R.L.; Moses, B.; Leidal, K.; Nauseef, W.M.; Griffith, T.S. Neutrophil stimulation with Mycobacterium bovis bacillus calmette-guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood 2005, 106, 3474-3482.
16. Simons, M.P.; Leidal, K.G.; Nauseef, W.M.; Griffith, T.S. TNF-related apoptosis-inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules. J. Leukoc. Biol. 2008, 83, 621-629.
17. Yang, F.; Shi, P.; Xi, X.; Yi, S.; Li, H.; Sun, Q.; Sun, M. Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC). Med. Oncol. 2006, 23, 191-204.
18. Walczak, H.; Miller, R.E.; Ariail, K.; Gliniak, B.; Griffith, T.S.; Kubin, M.; Chin, W.; Jones, J.; Woodward, A.; Le, T.; Smith, C.; Smolak, P.; Goodwin, R.G.; Rauch, C.T.; Schuh, J.C.; Lynch, D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 1999, 5, 157-163.
19. Ashkenazi, A.; Pai, R.C.; Fong, S.; Leung, S.; Lawrence, D.A.; Marsters, S.A.; Blackie, C.; Chang, L.; McMurtrey, A.E.; Hebert, A.; DeForge, L.; Koumenis, I.L.; Lewis, D.; Harris, L.; Bussiere, J.; Koeppen, H.; Shahrokh, Z.; Schwall, R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 1999, 104, 155-162.
20. Lin, T.; Zhang, L.; Davis, J.; Gu, J.; Nishizaki, M.; Ji, L.; Roth, J.A.; Xiong, M.; Fang, B. Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. Mol. Ther. 2003, 8, 441-448.
21. Huang, X.; Lin, T.; Gu, J.; Zhang, L.; Roth, J.A.; Stephens, L.C.; Yu, Y.; Liu, J.; Fang, B. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. Gene Ther. 2002, 9, 1379-1386.
22. Gurung, P.; Kucaba, T.A.; Schoenberger, S.P.; Ferguson, T.A.; Griffith, T.S. TRAIL-expressing CD8+ T cells mediate tolerance following soluble peptide-induced peripheral T cell deletion. J. Leukoc. Biol. 2010, 88, 1217-1225.
23. Brincks, E.L.; Katewa, A.; Kucaba, T.A.; Griffith, T.S.; Legge, K.L. CD8 T cells utilize TRAIL to control influenza virus infection. J. Immunol. 2008, 181, 4918-4925.
24. Janssen, E.M.; Droin, N.M.; Lemmens, E.E.; Pinkoski, M.J.; Bensinger, S.J.; Ehst, B.D.; Griffith, T.S.; Green, D.R.; Schoenberger, S.P. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005, 434, 88-93.
25. Pan, G.; O'Rourke, K.; Chinnaiyan, A.M.; Gentz, R.; Ebner, R.; Ni, J.; Dixit, V.M. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276, 111-113.
26. Pan, G.; Ni, J.; Wei, Y.F.; Yu, G.; Gentz, R.; Dixit, V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997, 277, 815-818.
27. Walczak, H.; Degli-Esposti, M.A.; Johnson, R.S.; Smolak, P.J.; Waugh, J.Y.; Boiani, N.; Timour, M.S.; Gerhart, M.J.; Schooley, K.A.; Smith, C.A.; Goodwin, R.G.; Rauch, C.T. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO J. 1997, 16, 5386-5397.
28. Sheridan, J.P.; Marsters, S.A.; Pitti, R.M.; Gurney, A.; Skubatch, M.; Baldwin, D.; Ramakrishnan, L.; Gray, C.L.; Baker, K.; Wood, W.I.; Goddard, A.D.; Godowski, P.; Ashkenazi, A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277, 818-821.
29. Degli-Esposti, M.A.; Dougall, W.C.; Smolak, P.J.; Waugh, J.Y.; Smith, C.A.; Goodwin, R.G. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997, 7, 813-820.
30. Marsters, S.A.; Sheridan, J.P.; Pitti, R.M.; Huang, A.; Skubatch, M.; Baldwin, D.; Yuan, J.; Gurney, A.; Goddard, A.D.; Godowski, P.; Ashkenazi, A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 1997, 7, 1003-1006.
31. Pan, G.; Ni, J.; Yu, G.; Wei, Y.F.; Dixit, V.M. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett. 1998, 424, 41-45.
32. Hymowitz, S.G.; Christinger, H.W.; Fuh, G.; Ultsch, M.; O'Connell, M.; Kelley, R.F.; Ashkenazi, A.; de Vos, A.M. Triggering cell death: The crystal structure of Apo2L/TRAIL in a complex with Death Receptor 5. Mol. Cell 1999, 4, 563-571.
33. Emery, J.G.; McDonnell, P.; Burke, M.B.; Deen, K.C.; Lyn, S.; Silverman, C.; Dul, E.; Appelbaum, E.R.; Eichman, C.; DiPrinzio, R.; Dodds, R.A.; James, I.E.; Rosenberg, M.; Lee, J.C.; Young, P.R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 1998, 273, 14363-14367.
34. Lacey, D.L.; Timms, E.; Tan, H.L.; Kelley, M.J.; Dunstan, C.R.; Burgess, T.; Elliott, R.; Colombero, A.; Elliott, G.; Scully, S.; Hsu, H.; Sullivan, J.; Hawkins, N.; Davy, E.; Capparelli, C.; Eli, A.; Qian, Y.X.; Kaufman, S.; Sarosi, I.; Shalhoub, V.; Senaldi, G.; Guo, J.; Delaney, J.; Boyle, W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93, 165-176.
35. Wu, G.S.; Burns, T.F.; Zhan, Y.; Alnemri, E.S.; El-Deiry, W.S. Molecular cloning and functional analysis of the mouse homologue of the Killer/DR5 tumor necrosis factor-related apoptosisinducing ligand (TRAIL) death receptor. Cancer Res. 1999, 59, 2770-2775.
36. Schneider, P.; Olson, D.; Tardivel, A.; Browning, B.; Lugovskoy, A.; Gong, D.; Dobles, M.; Hertig, S.; Hofmann, K.; Van Vlijmen, H.; Hsu, Y.M.; Burkly, L.C.; Tschopp, J.; Zheng, T.S. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Biol. Chem. 2003, 278, 5444-5454.
37. Sprick, M.R.; Weigand, M.A.; Rieser, E.; Rauch, C.T.; Juo, P.; Blenis, J.; Krammer, P.H.; Walczak, H. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000, 12, 599-609.
38. Kischkel, F.C.; Lawrence, D.A.; Chuntharapai, A.; Schow, P.; Kim, K.J.; Ashkenazi, A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000, 12, 611-620.
39. Li, H.; Zhu, H.; Xu, C.J.; Yuan, J. Cleavage of Bid by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94, 491-501.
40. Griffith, T.S.; Chin, W.A.; Jackson, G.C.; Lynch, D.H.; Kubin, M.Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 1998, 161, 2833-2840.
41. Irmler, M.; Thome, M.; Hahne, M.; Schneider, P.; Hofmann, K.; Steiner, V.; Bodmer, J.L.; Schroter, M.; Burns, K.; Mattmann, C.; Rimoldi, D.; French, L.E.; Tschopp, J. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388, 190-195.
42. Barnhart, B.C.; Alappat, E.C.; Peter, M.E. The CD95 type I/type II model. Semin. Immunol. 2003, 15, 185-193.
43. Du, C.; Fang, M.; Li, Y.; Li, L.; Wang, X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102, 33-42.
44. Verhagen, A.M.; Ekert, P.G.; Pakusch, M.; Silke, J.; Connolly, L.M.; Reid, G.E.; Moritz, R.L.; Simpson, R.J.; Vaux, D.L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102, 43-53.
45. Schulze-Osthoff, K.; Ferrari, D.; Los, M.; Wesselborg, S.; Peter, M.E. Apoptosis signaling by death receptors. Eur. J. Biochem. 1998, 254, 439-459.
46. Li, P.; Nijhawan, D.; Budihardjo, I.; Srinivasula, S.M.; Ahmad, M.; Alnemri, E.S.; Wang, X. Cytochrome c and dATP-dependent formation of APAF-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91, 479-489.
47. Kelley, S.K.; Harris, L.A.; Xie, D.; Deforge, L.; Totpal, K.; Bussiere, J.; Fox, J.A. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 2001, 299, 31-38.
48. Pollack, I.F.; Erff, M.; Ashkenazi, A. Direct stimulation of apoptotic signaling by soluble Apo2L/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin. Cancer Res. 2001, 7, 1362-1369.
49. Gazitt, Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 1999, 13, 1817-1824.
50. Kemp, C.J.; Sun, S.; Gurley, K.E. p53 induction and apoptosis in response to radio-and chemotherapy in vivo is tumor-type-dependent. Cancer Res. 2001, 61, 327-332.
51. Liu, X.; Yue, P.; Khuri, F.R.; Sun, S.Y. p53 upregulates Death Receptor 4 expression through an intronic p53 binding site. Cancer Res. 2004, 64, 5078-5083.
52. Takimoto, R.; El-Deiry, W.S. Wild-type p53 transactivates the Killer/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000, 19, 1735-1743.
53. Gliniak, B.; Le, T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res. 1999, 59, 6153-6158.
54. Chinnaiyan, A.M.; Prasad, U.; Shankar, S.; Hamstra, D.A.; Shanaiah, M.; Chenevert, T.L.; Ross, B.D.; Rehemtulla, A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. USA 2000, 97, 1754-1759.
55. Hingtgen, S.; Ren, X.; Terwilliger, E.; Classon, M.; Weissleder, R.; Shah, K. Targeting multiple pathways in gliomas with stem cell and viral delivered s-TRAILl and temozolomide. Mol. Cancer Ther. 2008, 7, 3575-3585.
56. Keane, M.M.; Ettenberg, S.A.; Nau, M.M.; Russell, E.K.; Lipkowitz, S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 1999, 59, 734-741.
57. Nimmanapalli, R.; Perkins, C.L.; Orlando, M.; O'Bryan, E.; Nguyen, D.; Bhalla, K.N. Pretreatment with paclitaxel enhances Apo-2 ligand/tumor necrosis factor-related apoptosisinducing ligand-induced apoptosis of prostate cancer cells by inducing Death Receptors 4 and 5 protein levels. Cancer Res. 2001, 61, 759-763.
58. Mizutani, Y.; Yoshida, O.; Miki, T.; Bonavida, B. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells. Clin. Cancer Res. 1999, 5, 2605-2612.
59. Matsubara, H.; Mizutani, Y.; Hongo, F.; Nakanishi, H.; Kimura, Y.; Ushijima, S.; Kawauchi, A.; Tamura, T.; Sakata, T.; Miki, T. Gene therapy with TRAIL against renal cell carcinoma. Mol. Cancer Ther. 2006, 5, 2165-2171.
60. Bonvini, P.; Zorzi, E.; Basso, G.; Rosolen, A. Bortezomib-mediated 26s proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia 2007, 21, 838-842.
61. Williams, S.A.; McConkey, D.J. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LnCAP-Pro5 prostate cancer cells. Cancer Res. 2003, 63, 7338-7344.
62. Sayers, T.J.; Brooks, A.D.; Koh, C.Y.; Ma, W.; Seki, N.; Raziuddin, A.; Blazar, B.R.; Zhang, X.; Elliott, P.J.; Murphy, W.J. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003, 102, 303-310.
63. Seki, N.; Toh, U.; Sayers, T.J.; Fujii, T.; Miyagi, M.; Akagi, Y.; Kusukawa, J.; Kage, M.; Shirouzu, K.; Yamana, H. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. Mol. Cancer Ther. 2010, 9, 1842-1851.
64. Brooks, A.D.; Ramirez, T.; Toh, U.; Onksen, J.; Elliott, P.J.; Murphy, W.J.; Sayers, T.J. The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis. Ann. N. Y. Acad. Sci. 2005, 1059, 160-167.
65. Rosato, R.R.; Almenara, J.A.; Coe, S.; Grant, S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 2007, 67, 9490-9500.
66. Llobet, D.; Eritja, N.; Yeramian, A.; Pallares, J.; Sorolla, A.; Domingo, M.; Santacana, M.; Gonzalez-Tallada, F.J.; Matias-Guiu, X.; Dolcet, X. The multikinase inhibitor sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur. J. Cancer 2010, 46, 836-850.
67. Kim, S.H.; Ricci, M.S.; El-Deiry, W.S. Mcl-1: A gateway to TRAIL sensitization. Cancer Res. 2008, 68, 2062-2064.
68. Johnstone, R.W. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 2002, 1, 287-299.
69. Norian, L.A.; Kucaba, T.A.; Earel, J.K.; Knutson, T.; Vanoosten, R.L.; Griffith, T.S. Synergistic induction of apoptosis in primary B-CLL cells after treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand and histone deacetylase inhibitors. J. Oncol. 2009, 2009, 408038.
70. Nakata, S.; Yoshida, T.; Horinaka, M.; Shiraishi, T.; Wakada, M.; Sakai, T. Histone deacetylase inhibitors upregulate Death Receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/Apo2-L in human malignant tumor cells. Oncogene 2004, 23, 6261-6271.
71. Fulda, S.; Debatin, K.M. Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur. J. Cancer 2005, 41, 786-798.
72. VanOosten, R.L.; Moore, J.M.; Karacay, B.; Griffith, T.S. Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer Biol. Ther. 2005, 4, 1104-1112.
73. Vanoosten, R.L.; Moore, J.M.; Ludwig, A.T.; Griffith, T.S. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol. Ther. 2005, 11, 542-552.
74. Fulda, S.; Debatin, K.M. HDAC inhibitors: Double edge sword for TRAIL cancer therapy? Cancer Biol. Ther. 2005, 4, 1113-1115.
75. Fulda, S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr. Cancer Drug Targets 2008, 8, 132-140.
76. Walther, W.; Stein, U. Viral vectors for gene transfer: A review of their use in the treatment of human diseases. Drugs 2000, 60, 249-271.
77. Young, L.S.; Searle, P.F.; Onion, D.; Mautner, V. Viral gene therapy strategies: From basic science to clinical application. J. Pathol. 2006, 208, 299-318.
78. Lai, C.M.; Lai, Y.K.; Rakoczy, P.E. Adenovirus and adeno-associated virus vectors. DNA Cell. Biol. 2002, 21, 895-913.
79. Ginsberg, H.S.; Pereira, H.G.; Valentine, R.C.; Wilcox, W.C. A proposed terminology for the adenovirus antigens and virion morphological subunits. Virology 1966, 28, 782-783.
80. Ballay, A.; Levrero, M.; Buendia, M.A.; Tiollais, P.; Perricaudet, M. In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumin from recombinant human adenoviruses. EMBO J. 1985, 4, 3861-3865.
81. Karlsson, S.; Van Doren, K.; Schweiger, S.G.; Nienhuis, A.W.; Gluzman, Y. Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors. EMBO J. 1986, 5, 2377-2385.
82. Jones, N.; Shenk, T. An adenovirus type 5 early gene function regulates expression of other early viral genes. Proc. Natl. Acad. Sci. USA 1979, 76, 3665-3669.
83. Kelly, T.J., Jr.; Lewis, A.M., Jr. Use of nondefective adenovirus-simian virus 40 hybrids for mapping the simian virus 40 genome. J. Virol. 1973, 12, 643-652.
84. Yang, Y.; Nunes, F.A.; Berencsi, K.; Gonczol, E.; Engelhardt, J.F.; Wilson, J.M. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat. Genet. 1994, 7, 362-369.
85. Bergelson, J.M.; Cunningham, J.A.; Droguett, G.; Kurt-Jones, E.A.; Krithivas, A.; Hong, J.S.; Horwitz, M.S.; Crowell, R.L.; Finberg, R.W. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275, 1320-1323.
86. Bergelson, J.M.; Krithivas, A.; Celi, L.; Droguett, G.; Horwitz, M.S.; Wickham, T.; Crowell, R.L.; Finberg, R.W. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J. Virol. 1998, 72, 415-419.
87. Wickham, T.J.; Mathias, P.; Cheresh, D.A.; Nemerow, G.R. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993, 73, 309-319.
88. Hemmi, S.; Geertsen, R.; Mezzacasa, A.; Peter, I.; Dummer, R. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum. Gene Ther. 1998, 9, 2363-2373.
89. Pearson, A.S.; Koch, P.E.; Atkinson, N.; Xiong, M.; Finberg, R.W.; Roth, J.A.; Fang, B. Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin. Cancer Res. 1999, 5, 4208-4213.
90. Jacob, D.; Davis, J.; Zhu, H.; Zhang, L.; Teraishi, F.; Wu, S.; Marini, F.C., 3rd; Fang, B. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Clin. Cancer Res. 2004, 10, 3535-3541.
91. Jacob, D.; Bahra, M.; Schumacher, G.; Neuhaus, P.; Fang, B. Gene therapy in colon cancer cells with a fiber-modified adenovector expressing the TRAIL gene driven by the hTERT promoter. Anticancer Res. 2004, 24, 3075-3079.
92. Jacob, D.; Schumacher, G.; Bahra, M.; Davis, J.; Zhu, H.B.; Zhang, L.D.; Teraishi, F.; Neuhaus, P.; Fang, B.L. Fiber-modified adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene from the human telomerase reverse transcriptase promoter induces apoptosis in human hepatocellular carcinoma cells. World J. Gastroenterol. 2005, 11, 2552-2556.
93. Mizuguchi, H.; Hayakawa, T. Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene 2002, 285, 69-77.
94. Wohlfahrt, M.E.; Beard, B.C.; Lieber, A.; Kiem, H.P. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res. 2007, 67, 8783-8790.
95. Wang, Y.G.; Wang, J.H.; Zhang, Y.H.; Gu, Q.; Liu, X.Y. Antitumor effect of a novel adenoassociated virus vector targeting to telomerase activity in tumor cells. Acta Biochim. Biophys. Sin. (Shanghai) 2004, 36, 492-500.
96. Jimenez, J.A.; Li, X.; Zhang, Y.P.; Bae, K.H.; Mohammadi, Y.; Pandya, P.; Kao, C.; Gardner, T.A. Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL. Cancer Gene Ther. 2010, 17, 180-191.
97. Griffith, T.S.; Anderson, R.D.; Davidson, B.L.; Williams, R.D.; Ratliff, T.L. Adenoviralmediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J. Immunol. 2000, 165, 2886-2894.
98. Griffith, T.S.; Broghammer, E.L. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol. Ther. 2001, 4, 257-266.
99. Armeanu, S.; Lauer, U.M.; Smirnow, I.; Schenk, M.; Weiss, T.S.; Gregor, M.; Bitzer, M. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res. 2003, 63, 2369-2372.
100. VanOosten, R.L.; Griffith, T.S. Activation of tumor-specific CD8+ T cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. Cancer Res. 2007, 67, 11980-11990.
101. Berns, K.I.; Giraud, C. Biology of adeno-associated virus. Curr. Top. Microbiol. Immunol. 1996, 218, 1-23.
102. Lu, Y. Recombinant adeno-associated virus as delivery vector for gene therapy--a review. Stem Cells Dev. 2004, 13, 133-145.
103. Kwon, I.; Schaffer, D.V. Designer gene delivery vectors: Molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm. Res. 2008, 25, 489-499.
104. Mohr, A.; Henderson, G.; Dudus, L.; Herr, I.; Kuerschner, T.; Debatin, K.M.; Weiher, H.; Fisher, K.J.; Zwacka, R.M. AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression. Gene Ther. 2004, 11, 534-543.
105. Yoo, J.; Choi, S.; Hwang, K.S.; Cho, W.K.; Jung, C.R.; Kwon, S.T.; Im, D.S. Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model. J. Gene Med. 2006, 8, 163-174.
106. Wu, Z.; Asokan, A.; Samulski, R.J. Adeno-associated virus serotypes: Vector toolkit for human gene therapy. Mol. Ther. 2006, 14, 316-327.
107. Shi, J.; Zheng, D.; Liu, Y.; Sham, M.H.; Tam, P.; Farzaneh, F.; Xu, R. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res. 2005, 65, 1687-1692.
108. Bremer, E.; de Bruyn, M.; Samplonius, D.F.; Bijma, T.; ten Cate, B.; de Leij, L.F.; Helfrich, W. Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells. J. Mol. Med. 2008, 86, 909-924.
109. Wang, Y.; Huang, F.; Cai, H.; Zhong, S.; Liu, X.; Tan, W.S. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma. J. Gene Med. 2008, 10, 518-526.
110. Zhang, Y.; Qu, Z.H.; Cui, M.; Guo, C.; Zhang, X.M.; Ma, C.H.; Sun, W.S. Combined endostatin and TRAIL gene transfer suppresses human hepatocellular carcinoma growth and angiogenesis in nude mice. Cancer Biol. Ther. 2009, 8, 466-473.
111. Wang, Y.; Ma, L.; Wang, S.; Bao, Y.; Ni, C.; Guan, N.; Zhao, J.; Fan, X. Assessment of CAR-or CD46-dependent adenoviral vector-mediated TRAIL gene therapy in clinical adenocarcinoma lung cancer cells. Oncology 2009, 77, 366-377.
112. Ma, H.; Liu, Y.; Liu, S.; Xu, R.; Zheng, D. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology 2005, 42, 1355-1363.
113. Wenger, T.; Mattern, J.; Haas, T.L.; Sprick, M.R.; Walczak, H.; Debatin, K.M.; Buchler, M.W.; Herr, I. Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and-independent effects. Cancer Gene Ther. 2007, 14, 316-326.
114. Mangipudi, S.S.; Canine, B.F.; Wang, Y.; Hatefi, A. Development of a genetically engineered biomimetic vector for targeted gene transfer to breast cancer cells. Mol. Pharm. 2009, 6, 1100-1109.